Hepatocellular carcinoma (HCC) immunotherapy by anti-PD-1 monoclonal antibodies: A rapidly evolving strategy.

Autor: Nikoo M; Department of Immunology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, Iran., Hassan ZF; College of Dentistry, Al-Ayen University, Thi-Qar, Iraq., Mardasi M; Biotechnology Department, Faculty of Life Sciences and Biotechnology, Shahid Beheshti University G. C., Evin, Tehran, Iran., Rostamnezhad E; Department of Molecular Genetics, Faculty of Advanced Science and Technology, Tehran Medical Science, Islamic Azad University, Tehran, Iran., Roozbahani F; Department of Microbiology and Virology, Faculty of Medicine, Mazandaran University of Medical Sciences, Sari, Iran., Rahimi S; Industrial and Environmental Biotechnology Department, National Institute of Genetic Engineering and Biotechnology(NIGEB), Tehran, Iran., Mohammadi J; Department of Life Science Engineering, Faculty of New Sciences and Technologies, University of Tehran, Tehran, Iran. Electronic address: javad.mohammadi@ut.ac.ir.

Publikováno v: Pathology, research and practice [Pathol Res Pract] 2023 Jul; Vol. 247, pp. 154473. Date of Electronic Publication: 2023 Apr 20.

Immune checkpoint inhibitor‑associated diabetes mellitus in patients with HCC: Report of three cases and literature review.

Autor: Wang, Gaocheng^1,2 (AUTHOR), Wang, Jingjing³ (AUTHOR), Dong, Shuilin¹ (AUTHOR), Zhang, Zhanguo¹ (AUTHOR), Zhang, Wanguang¹ (AUTHOR), Zhao, Jianping¹ (AUTHOR) xucuixiang1129@163.com

Publikováno v: Experimental & Therapeutic Medicine. May2024, Vol. 27 Issue 5, pN.PAG-N.PAG. 1p.